|
November 2001, Volume 1, Issue 2
|
What type of data should be collected | How to use the data in risk assessment |
---|---|
Human, age-related range of spontaneous mutation | Identify background mutant frequencies with no adverse effect |
Human, age-related range of mutation after exposure, occupational environmental or therapeutic | Using epidemiological data, establish the relative risk associated with a particular mutant frequency |
Rodent, age-related range of spontaneous mutation | Compare to human data for species extrapolation |
Rodent, age-related range of mutation frequency after mimicked human exposure | Define how rodent mutation induction relates to human risk, eventually predict risk in the absence of human data |
Figure 2. Experimental strategies for applying genotypic selection methods to cancer risk assessment.
Identifying the most useful mutational targets is a key issue in successfully applying genotypic selection to cancer risk assessment and is the first step in assay development. Ras was identified as a prototype for oncogene targets. The ras family of proteins (H-ras, N-ras, and K-ras) function as molecular switches in signal transduction pathways. The ras protein is a small (21 kDa) GTPase, which is in its active conformation when bound to GTP. The most common mutations in the ras gene result in protein species that bind GTP, but not GDP, and are, therefore, continuously active. Constitutive ras activity can cause continuous cell proliferation via the raf-MAPK pathway (see Figure 3, following this paragraph). However, this is not the only pathway affected by ras activity. It is becoming clear that there is extensive cross-talk between GTPase signaling pathways. Thus, the effect of continuous ras activity will depend on cell background and sometimes results in apoptosis.
Figure 3. Consequences of ras activation are dependent on cell-type specific signal transduction effector molecules. Two different outcomes of ras activation are depicted. In one pathway, active ras recruits raf to the membrane, facilitating the phosphorylation (activation) of raf. Raf then phosphorylates MEK (mitogen activated and extracellular response kinase), which phosphorylates ERK (extracellular response kinase), which translocates into the nucleus where it can activate transcription factors to increase cyclin D1 levels in the cell. Cyclin D1 (with its cofactors) phosphorylates pRB, which releases E2F, allowing E2F regulated proteins to be transcribed. At this point, the cell is committed to the S phase and cell proliferation (44). However, ras can also activate the expression of p16ARF (alternative reading frame), which is considered a tumor suppressor. P16ARF indirectly affects the activity of p53 by sequestering Mdm2 (an inhibitor of p53). In this case, the ras initiated pathway can lead to apoptosis (45).
Ras mutations frequently occur in both spontaneous and chemically induced rodent tumors and are localized to a few specific DNA regions, codons 12, 13, and 61 (21). Similar patterns of ras mutation are present in a number of different human tumor types. Ras mutation is found in 90% of pancreatic tumors, 50% of colon and thyroid tumors, and 30% of lung tumors and leukemias (22). The frequencies with which the most commonly occurring ras gene base substitutions have been detected in human tumors are given in Figure 4 (following this paragraph) (22-38). Thus, ras mutations are valuable targets to use in the development and application of genotypic selection methods.
Figure 4. Frequency of the most common ras mutations in human tumors. The frequency of each particular basepair substitution mutation was plotted. Only mutations that were detectable in less than or equal to 2% of the tumors of a particular tissue origin are included.
Some of the most powerful tools that have been used for genotypic selection are restriction enzymes. Digestion of DNA, with a restriction enzyme is used to selectively destroy wild-type DNA sequences. This effectively enriches for sequences not digested because they carried a mutation in the restriction enzyme cleavage site (19). A report by Ellis et al. suggested that the E. coli mismatch binding protein, MutS could be used similarly as a tool for the selective destruction of wild-type DNA sequence while avoiding the limitation of only being able to analyze restriction enzyme cleavage sites (39). In their "MutEx" assay, PCR products were synthesized, denatured, and reannealed; thereby creating heteroduplex molecules in the DNA from individuals that were heterozygous for a germline mutation. The E. coli MutS protein was incubated with the PCR products and the 3 - 5 exonuclease activity of T7 DNA polymerase was used to digest the heteroduplex DNA. The bound MutS protein blocked this digestion so that the length of the protected DNA fragment defined the position of the germline mutation in the PCR product being analyzed. Because homoduplex DNA would be degraded in such an assay, it was realized that this approach might also be used for genotypic selection; to selectively degrade a large excess of wild-type sequence while preserving mutant sequence. Consequently, this type of MutS selection was the basis for the first genotypic selection method developed at the NCTR.
The H-ras codon 61 CAA to AAA mutation was used as the model system in the development of the MutEx approach as a genotypic selection method. This mutation was selected because: 1) It is the most frequent mutation detected in mouse liver tumors, 2) its occurrence in tumors can be increased by chemical treatment, and 3) mouse strain differences in the frequency of this mutation might eventually be used for method validation (21). Therefore, mutant and wild-type mouse H-ras sequences were cloned and restriction fragments corresponding to each were isolated and quantified. These restriction fragments were used in reconstruction experiments; meaning that DNA mixtures with known mutant fractions were prepared and used in the analysis of different experimental procedures. The molecular events occurring in each step of the MutEx genotypic selection that was developed are depicted in Figure 5 (following this paragraph). The result of this genotypic selection is that a large proportion of the wild-type DNA molecules is destroyed while the mutant sequences are preserved. Mutant sequence was then detected using single nucleotide primer extension (SNuPE) (40). In SNuPE, the extension of a primer adjacent to the base being interrogated is carried out in the presence of a single nucleotide complementary to either the mutant or wild-type base. Using this approach it was determined that mutant fractions between 0.5 and 2 x 10-5 were detectable (41). In addition, it was determined that SNuPE alone had a sensitivity of less than or equal to 2 x 10-2. From this information it was concluded that the MutEx assay was providing an ~1,000-fold enrichment of mutant DNA sequences.
Figure 5. The MutEx/SNuPE genotypic selection method.
The second genotypic selection method that was developed at the NCTR was based on a completely different type of selection, allele-specific amplification. In an allele-specific amplification, a PCR primer that has more mismatches to the wild-type sequence than the mutant sequence is used to selectively amplify mutant DNA (19). Allele-specific competitive blocker PCR (ACB-PCR) is an allele-specific amplification method that was reported to have a sensitivity of 10-4 (42). The assay uses three different primers, a mutant-specific primer that amplifies the mutant sequence, a blocker primer that obstructs PCR amplification from the wild-type sequence, and an upstream PCR primer (see Figure 6 following this paragraph). At the NCTR, this approach was adapted to the detection of the H-ras codon 61 CAA to AAA mutation (43). The assay was modified in a number of ways, including the use of the Stoeffel fragment of Taq DNA polymerase and PerfectMatch PCR Enhancer. These modifications resulted in an increase in the assay sensitivity with mutant fractions as low as 10-5 being detectable.
Figure 6. Primer design used in allele-specific competitive blocker PCR (ACB-PCR). Three PCR primers are shown: the blocker primer (BP), mutant specific primer (MSP), and upstream primer (UP). The selective annealing of the MSP to mutant sequence and BP to wild-type sequence is depicted. These primer-template pairings result in single 3'-penultimate mismatches. These pairs are favored over annealing of the MSP to wild-type template or BP to mutant template, which would result in double 3'-terminal mismatches. The blocker primer carries a 3'-terminal dideoxy nucleotide and cannot be extended.
Keeping in mind that the goal of this work was to develop an assay that could detect spontaneous mutation (estimated at 10-7) neither the MutEx/SNuPE assay nor ACB-PCR alone had sufficient sensitivity. In an attempt to reach this sensitivity, the relatively insensitive mutation detection step of the MutEx/SNuPE assay was replaced by ACB-PCR. In other words, the MutEx mutant DNA enrichment was coupled with the sensitive ACB-PCR mutation detection method. This combined assay, named MutEx/ACB-PCR, was found to have a sensitivity of 10-7 in reconstruction experiments (see Figure 7 following this paragraph) (40). As a means of validating the use of this assay in the measurement of very low mutant fractions, the level of H-ras mutation induced by Pfu DNA polymerase during PCR amplification was determined. Pfu DNA polymerase was selected because it has the highest fidelity in replicating DNA sequences of any known thermostable polymerase and the most common error it produces is C to A transversion. The results from three replicate MutEx/ACB-PCR experiments measured the Pfu DNA polymerase-generated mutant fractions as 10 ± 3 x 10-7, from which a polymerase error rate of 8 ± 3 x 10-7 was calculated (40). This value is in good agreement with the published reports regarding Pfu DNA polymerase error rate and, therefore, substantiates the accuracy of the MutEx/ACB-PCR assay in the measurement of low mutant fractions.
Figure 7. The MutEx/ACB-PCR assay developed at NCTR has a sensitivity of 10-7. In the reconstruction experiment shown, each reaction contained 300 nanograms of genomic DNA and 3 x 107 copies of wild-type H-ras restriction fragment. Addition of different amounts of mutant restriction fragment was used to generate the mutant fraction standards analyzed (10-4 10-7). The signal in the 10-7 lanes corresponds to the detection of three mutant H-ras molecules in the presence of 3 x 107 wild-type alleles.
Genotypic selection is being developed as an approach for improving chemical risk assessment. This is primarily because the biomarkers that will be measured by genotypic selection, oncogene and tumor suppressor gene mutations, have a direct relationship to cancer. At the NCTR, work toward this goal has proceeded in two areas: 1) identifying the theoretical issues that should be considered in the development of new assays and 2) the assay development itself. For example, evidence that an average spontaneous mutation frequency of 10-7 might be expected was important for setting a goal for assay sensitivity. That goal, the detection of mutant allele in the presence of a 107-fold excess of wild-type allele is now achievable using the MutEx/ACB-PCR assay. However, additional challenges remain. In order to take advantage of MutEx/ACB-PCR sensitivity, a pool containing >107 molecules must be analyzed. This corresponds to a genomic DNA sample of >100 micrograms, a mass that would inhibit the sensitive MutEx/ACB-PCR approach. PCR amplification of target DNA cannot be used to generate the necessary DNA pool because the error rate of even the most reliable thermostable polymerase is higher than the level of mutation that needs to be detected (10-7). Thus, the development of gene-specific enrichment techniques is viewed as necessary, and development of such techniques is currently underway at the NCTR. Ultimately, the measurement of a small battery of oncogene and tumor suppressor gene mutations will be necessary to understand chemical-specific effects. Therefore, the genotypic selection assays already developed are being adapted to new mutational targets, namely human and rodent K-ras mutations. Eventually, the information provided by these sensitive assays should support a more scientifically rigorous approach to cancer risk assessment.
We wish to thank Martha Moore and Robert Heflich for their helpful suggestions in preparing this manuscript.
Conolly, R. B., Beck, B. D., and Goodman, J. I. 1999. Stimulating research to improve the scientific basis of risk assessment. Toxicological Sciences 49:1-4.
Gaylor, D. W., Axelrad, J. A., Brown, R. P., Cavagnaro, J. A., Cyr, W. H., Hulebak, K. L., Lorentzen, R. J., Miller, M. A., Mulligan, L. T., and Schwetz, B. A. 1997. Health risk assessment practices in the U.S. Food and Drug Administration. Regulatory Toxicology & Pharmacology 26:307-21.
Zeiger, E. 1998. Identification of rodent carcinogens and noncarcinogens using genetic toxicity tests: premises, promises, and performance. Regulatory Toxicology & Pharmacology 28:85-95.
Gold, L. S., Slone, T. H., and Ames, B. N. 1998. What do animal cancer tests tell us about human cancer risk?: Overview of analyses of the carcinogenic potency database. Drug Metabolism Reviews 30:359-404.
Golden, R. J., Holm, S. E., Robinson, D. E., Julkunen, P. H., and Reese, E. A. 1997. Chloroform mode of action: implications for cancer risk assessment. Regulatory Toxicology & Pharmacology 26:142-55.
Ames, B. N. and Gold, L. S. 1990. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science 249:970-1.
Goodman, J. I. 1998. The traditional toxicologic paradigm is correct: dose influences mechanism. Environmental Health Perspectives 106:285-8.
Lutz, W. K. and Kopp-Schneider, A. 1999. Threshold dose response for tumor induction by genotoxic carcinogens modeled via cell-cycle delay. Toxicological Sciences 49:110-5.
Sielken, R. L., Bretzlaff, R. S., and Stevenson, D. E. 1995. Challenges to default assumptions stimulate comprehensive realism as a new tier in quantitative cancer risk assessment. Regulatory Toxicology & Pharmacology 21:270-80.
Lutz, W. K. 2000. A true threshold dose in chemical carcinogenesis cannot be defined for a population, irrespective of the mode of action. Human & Experimental Toxicology 19:566-8; discussion 571-2.
Gaylor, D. W., Chen, J. J., and Sheehan, D. M. 1993. Uncertainty in cancer risk estimates. Risk Analysis 13:149-54.
Dellarco, V. L. and Wiltse, J. A. 1998. US Environmental Protection Agency's revised guidelines for Carcinogen Risk Assessment: incorporating mode of action data. Mutation Research 405:273-7.
Andersen, M. E., Meek, M. E., Boorman, G. A., Brusick, D. J., Cohen, S. M., Dragan, Y. P., Frederick, C. B., Goodman, J. I., Hard, G. C., O'Flaherty, E. J., and Robinson, D. E. 2000. Lessons learned in applying the U.S. EPA proposed cancer guidelines to specific compounds. Toxicological Sciences 53:159-72.
Beland, F. A., Hamilton, L. P., and Marques, M. M. 1999. Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. Carcinogenesis 20:471-477.
Casciano, D. A., Aidoo, A., Chen, T., Mittelstaedt, R. A., Manjanatha, M. G., and Heflich, R. H. 1999. Hprt mutant frequency and molecular analysis of Hprt mutations in rats treated with mutagenic carcinogens. Mutation Research 431:389-95.
Dobrovolsky, V. N., Casciano, D. A., and Heflich, R. H. 1999. Tk+/- mouse model for detecting in vivo mutation in an endogenous, autosomal gene. Mutation Research 423:125-36.
Hanahan, D. and Weinberg, R. A. 2000. The hallmarks of cancer. Cell 100:57-70.
Parsons, B. L. and Heflich, R. H. 1997. Genotypic selection methods for the direct analysis of point mutations. Mutation Research 387:97-121.
McKinzie, P. B., Delongchamp, R. R., Heflich, R. H., and Parsons, B. L. 2001. Prospects for applying genotypic selection of somatic oncomutation to chemical risk assessment. Mutation Research in press.
Maronpot, R. R., Fox, T., Malarkey, D. E., and Goldsworthy, T. L. 1995. Mutations in the ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 101:125-56.
Bos, J. L. 1989. ras oncogenes in human cancer: a review. Cancer Research 49:4682-9.
Ooi, A., Herz, F., Ii, S., Cordon-Cardo, C., Fradet, Y., and Mayall, B. H. 1994. Ha-ras codon 12 mutation in papillary tumors of the urinary bladder. A retrospective study. International Journal of Oncology 4:85-90.
Knowles, M. A. and Williamson, M. 1993. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Research 53:133-9.
Czerniak, B., Cohen, G. L., Etkind, P., Deitch, D., Simmons, H., Herz, F., and Koss, L. G. 1992. Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Human Pathology 23:1199-204.
Czerniak, B., Deitch, D., Simmons, H., Etkind, P., Herz, F., and Koss, L. G. 1990. Ha-ras gene codon 12 mutation and DNA ploidy in urinary bladder carcinoma. British Journal of Cancer 62:762-3.
Zhang, H., Nordenskjold, B., Dufmats, M., Soderkvist, P., and Sun, X. F. 1998. K-ras mutations in colorectal adenocarcinomas and neighbouring transitional mucosa. European Journal of Cancer 34:2053-7.
el Sebai, H., Ged, C., Bonichon, F., de Verneuil, H., and Longy, M. 1998. Genetic alterations in colorectal cancer, comparative analysis of deletion events, and point mutations. Cancer Genetics & Cytogenetics 104:32-8.
Smit, V. T., Boot, A. J., Smits, A. M., Fleuren, G. J., Cornelisse, C. J., and Bos, J. L. 1988. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Research 16:7773-82.
Keohavong, P., DeMichele, M. A., Melacrinos, A. C., Landreneau, R. J., Weyant, R. J., and Siegfried, J. M. 1996. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clinical Cancer Research 2:411-8.
Vachtenheim, J., Horakova, I., Novotna, H., Opaalka, P., and Roubkova, H. 1995. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. Clinical Cancer Research 1:359-65.
Hruban, R. H., van Mansfeld, A. D., Offerhaus, G. J., van Weering, D. H., Allison, D. C., Goodman, S. N., Kensler, T. W., Bose, K. K., Cameron, J. L., and Bos, J. L. 1993. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. American Journal of Pathology 143:545-54.
Grunewald, K., Lyons, J., Frohlich, A., Feichtinger, H., Weger, R. A., Schwab, G., Janssen, J. W., and Bartram, C. R. 1989. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. International Journal of Cancer 43:1037-41.
Kondo, H., Sugano, K., Fukayama, N., Kyogoku, A., Nose, H., Shimada, K., Ohkura, H., Ohtsu, A., Yoshida, S., and Shimosato, Y. 1994. Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 73:1589-94.
Tamagawa, E., Ueda, M., Takahashi, S., Sugano, K., Uematsu, S., Mukai, M., Ogata, Y., and Kitajima, M. 1997. Pancreatic lymph nodal and plexus micrometastases detected by enriched polymerase chain reaction and nonradioisotopic single-strand conformation polymorphism analysis: a new predictive factor for recurrent pancreatic carcinoma. Clinical Cancer Research 3:2143-9.
Enomoto, T., Inoue, M., Perantoni, A. O., Buzard, G. S., Miki, H., Tanizawa, O., and Rice, J. M. 1991. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Research 51:5308-14.
Enomoto, T., Inoue, M., Perantoni, A. O., Terakawa, N., Tanizawa, O., and Rice, J. M. 1990. K-ras activation in neoplasms of the human female reproductive tract. Cancer Research 50:6139-45.
Mizuuchi, H., Nasim, S., Kudo, R., Silverberg, S. G., Greenhouse, S., and Garrett, C. T. 1992. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Research 52:2777-81.
Ellis, L. A., Taylor, G. R., Banks, R., and Baumberg, S. 1994. MutS binding protects heteroduplex DNA from exonuclease digestion in vitro: a simple method for detecting mutations. Nucleic Acids Research 22:2710-1.
Parsons, B. L. and Heflich, R. H. 1998. Detection of basepair substitution mutation at a frequency of 1 x 10(-7) by combining two genotypic selection methods, MutEx enrichment and allele-specific competitive blocker PCR. Environmental & Molecular Mutagenesis 32:200-11.
Parsons, B. L. and Heflich, R. H. 1997. Evaluation of MutS as a tool for direct measurement of point mutations in genomic DNA. Mutation Research 374:277-85.
Orou, A., Fechner, B., Utermann, G., and Menzel, H. J. 1995. Allele-specific competitive blocker PCR: a one-step method with applicability to pool screening. Human Mutation 6:163-9.
Parsons, B. L. and Heflich, R. H. 1998. Detection of a mouse H-ras codon 61 mutation using a modified allele-specific competitive blocker PCR genotypic selection method. Mutagenesis 13:581-8.
Pincus, M. R., Brandt-Rauf, P. W., Michl, J., Carty, R. P., and Friedman, F. K. 2000. ras-p21-induced cell transformation: unique signal transduction pathways and implications for the design of new chemotherapeutic agents. Cancer Investigation 18:39-50.
Sherr, C. J. 2000. The Pezcoller lecture: cancer cell cycles revisited. Cancer Research 60:3689-95.
The Authors
Pictured left to right:
Page B. McKinzie, Ph.D.
and Barbara L. Parsons, Ph.D.,
September 18, 2001
(NCTR Photo: Virginia B. Taylor)
Barbara L. Parsons is a FDA Staff Fellow in the Division of Genetic and Reproductive Toxicology at the National Center for Toxicological Research (NCTR), Jefferson, Arkansas. Dr. Parsons began her scientific career as a technician at Cold Spring Harbor Laboratory, Cold Spring Harbor, NY where she was involved in sequencing the Adenovirus genome. She entered the Department of Microbiology and Immunology and Interdisciplinary Program in Genetics at Duke University in 1982 and received her Ph.D. in 1988. During this time, her research was focused on animal virology; investigating the structure and function of Orthopoxvirus telomeres. Her first post-doctoral position was at the Beltsville Agricultural Research Center in Beltsville, Maryland where she studied changes in tomato fruit gene expression induced by wounding and the plant hormone, ethylene. Dr. Parsons began her work at the NCTR in 1994 when she was hired as a post-doctoral fellow through the Oak Ridge Institute for Science and Engineering (ORISE); work she continues now as an FDA Staff Fellow. Dr. Parsons was recently elected as a Councilor of the Environmental Mutagen Society. Her research interests lie in the development of DNA-based mutation detection methods and their application to cancer risk assessment.
Page B. McKinzie is an ORISE post-doctoral fellow in the Division of Genetic and Reproductive Toxicology at NCTR. Dr. McKinzie entered the graduate program of the Department of Biochemistry and Molecular Genetics in 1987 at the University of Alabama at Birmingham (UAB) and received her Ph.D. degree in 1993. Her graduate work was on the use of liposomes that are sensitive to low pH as a delivery vehicle for superoxide dismutase into fetal lung epithelial cells as an approach for relieving symptoms of bronchopulmonary dysplasia. Her subsequent post-doctoral position was with the Gene Therapy Program at UAB, with work focusing on: 1) using single-chain antibodies to knock out protein functions associated with carcinogenesis and 2) using replication deficient adenovirus as a vehicle for delivery of DNA into HPV-18 infected cells, with the goal of killing those cells. She began her work with the NCTR in 1999 and is currently adapting the DNA-based mutation detection methods developed at the NCTR to the detection of human and rat K-ras mutations.
Norris Alderson, Ph.D. - Office of the Commissioner (OC)
Daniel A. Casciano, Ph.D. National Center for Toxicological Research (NCTR)
Thomas A. Cebula, Ph.D. Center for Food Safety and Applied Nutrition
(CFSAN)
Lireka P. Joseph, Ph.D. Center for Devices and Radiological Health
(CDRH)
Joanne N. Locke Office of the Commissioner (OC)
Edward E. Max, Ph.D. Center for Biologics Evaluation and Research
(CBER)
Michael C. Olson Office of Regulatory Affairs (ORA)
Frank D. Sistare, Ph.D. Center for Drug Evaluation and Research (CDER)
Mary S. Wolfe, Ph.D. National Institute of Environmental Health Science
(NIEHS)
Linda D. Youngman, Ph.D. Center for Veterinary Medicine (CVM)
Hal Zenick , Ph.D. Environmental Protection Agency (EPA)
Note: New members from ATSDR and NIOSH will join the Regulatory
Research Perspectives Editorial Board in future issues.
Address for editorial matters:
DHHS/FDA/Jefferson Labs
National Center for Toxicological Research
3900 NCTR Road, HFT-1
Jefferson, Arkansas 72079-9502
Telephone: (870) 543-7516
web site: http://www.fda.gov/nctr
Article may be republished without permission. Credit to Regulatory Research
Perspectives as the source is appreciated.
Managing Editor/Layout: Virginia B. Taylor (email:
virginia.taylor@fda.hhs.gov )